Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC)- A Number-Needed-To-Treat (NNT) Analysis
Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.418
https://www.valueinhealthjournal.com/article/S1098-3015(13)02323-1/fulltext
Title :
Benefit of Adding Panitumumab to FOLFOX4 in Patients with KRAS/NRAS Wild-Type (WT) Metastatic Colorectal Cancer (mCRC)- A Number-Needed-To-Treat (NNT) Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)02323-1&doi=10.1016/j.jval.2013.08.418
First page :
A395
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
401